Menu Search
Equities

GSK plc

GSK:NYQ

GSK plc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)42.43
  • Today's Change-0.13 / -0.31%
  • Shares traded3.52m
  • 1 Year change+13.60%
  • Beta0.6665
Data delayed at least 15 minutes, as of Sep 19 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy2
Outperform1
Hold4
Sell1
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for GSK plc (ADR) have a median target of 46.50, with a high estimate of 54.00 and a low estimate of 39.30. The median estimate represents a 9.59% increase from the last price of 42.43.
High27.3%54.00
Med9.6%46.50
Low-7.4%39.30

Dividends in USD

Historical dividend information is not available for GSK plc.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On Jul 31, 2024, GSK plc (ADR) reported 2nd quarter 2024 earnings of 1.10 per share. This result exceeded the 0.99 consensus of the 2 analysts covering the company and exceeded last year's 2nd quarter results by 12.65%.
The next earnings announcement is expected on Oct 30, 2024.
Average growth rate+10.02%
GSK plc (ADR) reported annual 2023 earnings of 3.86 per share on Jan 31, 2024.
Average growth rate-0.18%
More ▼

Revenue history & estimates in USD

GSK plc (ADR) had 2nd quarter 2024 revenues of 9.95bn. This bettered the 9.62bn consensus of the 3 analysts covering the company. This was 17.78% above the prior year's 2nd quarter results.
Average growth rate+2.91%
GSK plc (ADR) had revenues for the full year 2023 of 37.70bn. This was 4.43% above the prior year's results.
Average growth rate-2.45%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.